Session (CTI)

PURPOSE: As states begin to regulate drug pricing and affordability through Prescription Drug Affordability Boards (PDABs), stakeholders face new challenges in navigating state-level pricing limits, affordability reviews, and evidence generation. This session will provide an in-depth PDAB overview covering the core functions of PDABs, how they assess drug affordability, and what impactful evidence can be prepared to engage with PDABs effectively. We will discuss the evolving landscape of PDABs, how they assess factors like cost, utilization, and out-of-pocket costs, and how pharmaceutical companies can adapt and evolve the evidence strategy to meet these state-specific regulatory requirements. The session will provide product case examples from Colorado and Maryland PDAB reviews and discuss learnings on recent affordability reviews, reimbursement methodologies evaluated, implications on patient access, and strategies for evidence generation. DESCRIPTION: Dr. Ramsey will moderate and spend 10 minutes defining PDABs, states that utilize them, and their roles. Dr. Padula will spend 15 minutes focusing on Upper Payment Limit (UPL) setting processes along state legislative considerations on drug pricing thresholds and value demonstration. Dr. Patel will spend 20 minutes reviewing the specific drug affordability review process across states, including key trends in how state PDABS are evaluating affordability (costs to system, utilization, out-of-pocket expenses). Dr. Patel will provide practical recommendations for key stakeholders to optimize engagement in PDABs to balance affordability and access to innovative treatments. 15 minutes will include real-time polling for the product case examples to gather audience perspectives with interactive discussion and question and answers from obtain practical insights and solutions. Attendees from life sciences industry professionals, payers, patient organizations, policymakers, and researchers will benefit from this session.